We’re pleased to confirm that the AUSSIE study has now been published in BJU International¹. The Australian study provides important new evidence that Cxbladder Triage Plus performs consistently across different patient populations and health systems.

Triage Plus is a 2nd generation Cxbladder test that combines mRNA and DNA biomarkers to enhance the risk stratification of patients presenting with hematuria.²

The findings of the AUSSIE study reproduce the performance seen in the recent DRIVE study³. They give clinicians and hospitals further peer-reviewed evidence supporting the use of the test to help rule out urothelial cancer and defer unnecessary invasive cystoscopies in patients with a low probability of disease.

The AUSSIE study enrolled 691 evaluable patients presenting with visible (gross) or non-visible (micro) haematuria across four Australian hospital urology clinics between September 2023 and August 2025:

• Test-negative rates of 81% in microhematuria (NPV 100%) and 70% in grosshematuria (NPV 98%). The overall test-negative rate (anticipated rule-out rate) was 74%.
• NPV remained at or above 99% across all microhematuria risk categories, while the proportion of patients testing negative appropriately declined as underlying disease risk increased.
• 16 tumours identified by Cxbladder Triage Plus but not identified by imaging.
• All high-grade tumors (32/32) including CIS were detected by Cxbladder Triage Plus.

Read the study published in BJU International.

To discuss the findings, local availability, and how Triage Plus can support a risk stratified hematuria pathway, please contact us.

¹ Buhariwalla, V., Sethi, K., Vela, I., Hayne, D., Atchia, Z., de Lange, M., Lough, T., White, A. and Ranasinghe, W. (2026), Validation of Cxbladder Triage Plus in Australian patients with haematuria: the AUSSIE study. BJU Int. https://doi.org/10.1111/bju.70504
² Savage et al. (2026). Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study. Urologic oncology, 44(1), 65.e13–65.e20. https://doi.org/10.1016/j.urolonc.2025.10.008